These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19220256)

  • 1. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.
    Flaig TW; Su LJ; McCoach C; Li Y; Raben D; Varella-Garcia M; Bemis LT
    BJU Int; 2009 Jun; 103(12):1729-37. PubMed ID: 19220256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cells.
    Li Y; Yang X; Su LJ; Flaig TW
    Oncol Rep; 2010 Oct; 24(4):1019-28. PubMed ID: 20811684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
    Gustafson DL; Frederick B; Merz AL; Raben D
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):179-88. PubMed ID: 17393165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
    Naumov GN; Nilsson MB; Cascone T; Briggs A; Straume O; Akslen LA; Lifshits E; Byers LA; Xu L; Wu HK; Jänne P; Kobayashi S; Halmos B; Tenen D; Tang XM; Engelman J; Yeap B; Folkman J; Johnson BE; Heymach JV
    Clin Cancer Res; 2009 May; 15(10):3484-94. PubMed ID: 19447865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line.
    Monteverde M; Tonissi F; Fischel JL; Etienne-Grimaldi MC; Milano G; Merlano M; Lo Nigro C
    Urol Oncol; 2013 Aug; 31(6):776-86. PubMed ID: 21795074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
    Morabito A; Piccirillo MC; Falasconi F; De Feo G; Del Giudice A; Bryce J; Di Maio M; De Maio E; Normanno N; Perrone F
    Oncologist; 2009 Apr; 14(4):378-90. PubMed ID: 19349511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
    Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
    Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Significant Role of Cyclin D1 in the Synergistic Growth-inhibitory Effect of Combined Therapy of Vandetanib with 5-Fluorouracil for Gastric Cancer.
    Yawata K; Osada S; Tanahashi T; Matsui S; Sasaki Y; Tanaka Y; Okumura N; Matsuhashi N; Takahashi T; Yamaguchi K; Yoshida K
    Anticancer Res; 2016 Oct; 36(10):5215-5226. PubMed ID: 27798882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.
    Troiani T; Serkova NJ; Gustafson DL; Henthorn TK; Lockerbie O; Merz A; Long M; Morrow M; Ciardiello F; Eckhardt SG
    Clin Cancer Res; 2007 Nov; 13(21):6450-8. PubMed ID: 17975157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly increases apoptosis.
    Munk M; Memon AA; Nexo E; Sorensen BS
    BJU Int; 2007 Jan; 99(1):196-201. PubMed ID: 17092291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid.
    Zage PE; Zeng L; Palla S; Fang W; Nilsson MB; Heymach JV; Zweidler-McKay PA
    Cancer; 2010 May; 116(10):2465-75. PubMed ID: 20225331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms.
    Jiang Y; Yuan Q; Fang Q
    J Cancer Res Clin Oncol; 2014 Jul; 140(7):1087-95. PubMed ID: 24728492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
    Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells.
    Li Y; Yang X; Su LJ; Flaig TW
    Urology; 2011 Jul; 78(1):233.e7-13. PubMed ID: 21529900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.
    Siegfried JM; Gubish CT; Rothstein ME; Henry C; Stabile LP
    J Thorac Oncol; 2012 Mar; 7(3):485-95. PubMed ID: 22258476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
    Lyros O; Mueller A; Heidel F; Schimanski CC; Gockel I; Galle PR; Lang H; Moehler M
    Int J Cancer; 2010 Sep; 127(5):1197-208. PubMed ID: 20039326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with cisplatin, on apoptosis in SCC-15 cells.
    Al-Hazzaa A; Bowen ID; Randerson P; Birchall MA
    Cell Prolif; 2005 Apr; 38(2):77-86. PubMed ID: 15842252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptosis of bladder cancer by sodium butyrate and cisplatin.
    Maruyama T; Yamamoto S; Qiu J; Ueda Y; Suzuki T; Nojima M; Shima H
    J Infect Chemother; 2012 Jun; 18(3):288-95. PubMed ID: 22041988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.
    Ciardiello F; Caputo R; Damiano V; Caputo R; Troiani T; Vitagliano D; Carlomagno F; Veneziani BM; Fontanini G; Bianco AR; Tortora G
    Clin Cancer Res; 2003 Apr; 9(4):1546-56. PubMed ID: 12684431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo.
    Colquhoun AJ; Mchugh LA; Tulchinsky E; Kriajevska M; Mellon JK
    J Radiat Res; 2007 Sep; 48(5):351-60. PubMed ID: 17609586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.